On March 17, the National Comprehensive Cancer Network (NCCN) updated its 2026 Clinical Practice Guidelines to include ANKTIVA in combination with BCG for treating patients with BCG-unresponsive non-muscle invasive bladder cancer. On March 24, ImmunityBio's shares fell by 20% after the U.S. Food and Drug Administration issued a warning letter regarding a television advertisement and podcast promoting its cancer therapy, which were deemed false or misleading and in violation of federal law.
